About Kodiak Sciences
Kodiak Sciences is a company based in Palo Alto (United States) founded in 2009.. Kodiak Sciences has raised $35.84 million across 3 funding rounds from investors including Perceptive Advisors and ArrowMark Partners. The company has 109 employees as of December 31, 2024. Kodiak Sciences offers products and services including Tarcocimab Tedromer, KSI-501, and KSI-101. Kodiak Sciences operates in a competitive market with competitors including argenx, MacroGenics, Alexion, Zai Lab and Visterra, among others.
- Headquarter Palo Alto, United States
- Employees 109 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Kodiak Sciences Inc
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-176.21 M32.36as on Dec 31, 2024
-
EBITDA
$-160.14 M36.29as on Dec 31, 2024
-
Total Equity Funding
$35.84 M (USD)
in 3 rounds
-
Latest Funding Round
$33 M (USD), Debt – Conventional
Apr 26, 2018
-
Investors
Perceptive Advisors
& 1 more
-
Employee Count
109
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Kodiak Sciences
Kodiak Sciences is a publicly listed company on the NASDAQ with ticker symbol KOD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Kodiak Sciences
Kodiak Sciences offers a comprehensive portfolio of products and services, including Tarcocimab Tedromer, KSI-501, and KSI-101. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Provides durable treatment for retinal vascular diseases through biopolymer conjugates.
Targets inflammation and permeability in high-prevalence retinal conditions.
Treats macular edema linked to inflammation in retinal disorders.
Unlock access to complete
Unlock access to complete
Funding Insights of Kodiak Sciences
Kodiak Sciences has successfully raised a total of $35.84M across 3 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $33 million completed in April 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Debt – Conventional — $33.0M
-
First Round
First Round
(21 Jul 2009)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2018 | Amount | Debt – Conventional - Kodiak Sciences | Valuation |
investors |
|
| Mar, 2016 | Amount | Series B - Kodiak Sciences | Valuation |
investors |
|
| Jul, 2009 | Amount | Seed - Kodiak Sciences | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Kodiak Sciences
Kodiak Sciences has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Perceptive Advisors and ArrowMark Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
Diversified asset management services are provided to investors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Kodiak Sciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Kodiak Sciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Kodiak Sciences Comparisons
Competitors of Kodiak Sciences
Kodiak Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as argenx, MacroGenics, Alexion, Zai Lab and Visterra, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company focused on cancer therapeutics development.
|
|
| domain | founded_year | HQ Location |
Therapies for rare and devastating diseases are developed by Alexion.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapies for cancers and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of monoclonal antibodies against infectious diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Kodiak Sciences
Frequently Asked Questions about Kodiak Sciences
When was Kodiak Sciences founded?
Kodiak Sciences was founded in 2009.
Where is Kodiak Sciences located?
Kodiak Sciences is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Is Kodiak Sciences a funded company?
Kodiak Sciences is a funded company, having raised a total of $35.84M across 3 funding rounds to date. The company's 1st funding round was a Seed of $1.84M, raised on Jul 21, 2009.
How many employees does Kodiak Sciences have?
As of Dec 31, 2024, the latest employee count at Kodiak Sciences is 109.
What does Kodiak Sciences do?
The company was founded in 2009 in Palo Alto, United States, and operates in the biotechnology sector. Focus is placed on developing therapeutics for retinal diseases, with two candidates in clinical stages: KSI-301 targeted at age-related macular degeneration and KSI-501 for dry age-related macular degeneration. These products are based on proprietary antibody bioconjugate platforms, supporting treatment advancements in ophthalmology.
Who are the top competitors of Kodiak Sciences?
Kodiak Sciences's top competitors include argenx, Zai Lab and MacroGenics.
What products or services does Kodiak Sciences offer?
Kodiak Sciences offers Tarcocimab Tedromer, KSI-501, and KSI-101.
Is Kodiak Sciences publicly traded?
Yes, Kodiak Sciences is publicly traded on NASDAQ under the ticker symbol KOD.
Who are Kodiak Sciences's investors?
Kodiak Sciences has 2 investors. Key investors include Perceptive Advisors, and ArrowMark Partners.
What is Kodiak Sciences's ticker symbol?
The ticker symbol of Kodiak Sciences is KOD on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.